Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.

doi:10.1186/bcr2857

Article

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.

Breast cancer research : BCR - 1 Apr 2011

Teng Yvonne Hui-Fang, Tan Wai-Jin, Thike Aye-Aye, Cheok Poh-Yian, Tse Gary Man-Kit, Wong Nan-Soon, Yip George Wai-Cheong, Bay Boon-Huat, Tan Puay-Hoon

Abstract excerpt

INTRODUCTION: Triple negative breast cancer is associated with poorer prognosis and unresponsiveness to endocrine and anti-HER2 directed agents. Despite emerging data supporting the use of polyADP-ribose polymerase (PARP) inhibitors, complete and durable responses are rare and exploration of additional targeted therapies is needed. Epidermal growth factor receptor (EGFR) is expressed in triple negative breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.

Abstract excerpt

Topics

Related research